Question 1

What are the potential benefits of participating in this trial compared to standard treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC clinical trial (NCT06977828). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the possible side effects of the treatments involved in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC clinical trial (NCT06977828). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC clinical trial (NCT06977828). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC clinical trial (NCT06977828). Contact the study team or your healthcare provider for specific answers.

Question 5

How long will I need to participate in the trial, and what will my visits look like?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC clinical trial (NCT06977828). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC clinical trial (NCT06977828). Contact the study team or your healthcare provider for specific answers.

What this study is about